January - March 2009

March 31, 2009		Takeda to Create Global Centers of Excellence
March 30, 2009		Takeda Expands its Own Sales and Marketing Operations in Europe
March 30, 2009		Takeda Submitted a New Drug Application in Japan for Fixed Dose Combination of Blopress® and Amlodipine Besylate
March 27, 2009		Takeda Establishes Presence in Canada
March 26, 2009		Takeda Submitted an Application for an Additional Indication of "Takepron® Capsules 15" and "Takepron® OD Tablets 15" in Japan for Prevention of Onset of low-dose aspirin related gastric and duodenal ulcer
March 24, 2009		Approval of an Additional Indication for ACTOS® in Japan;　Concomitant Therapy with Insulin for Type 2 Diabetes
March 23, 2009		Marketing Authorisation for Prostap® to Transfer Back to Takeda from Wyeth in the UK and Republic of Ireland
March 18, 2009		Takeda Submitted a New Drug Application for Lampion® in Japan for Treatment of secondary eradication of Helicobacter pylori
March 13, 2009		Launch of ECARD® LD and ECARD® HD in Japan
March 13, 2009		ULORIC® (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout
March 6, 2009		Takeda Receives New Information on Alogliptin (SYR-322) NDA
March 3, 2009		Millennium Initiates Two Phase 2 Trials of Novel Aurora A Kinase Inhibitor
February 24, 2009		Approval of an Additional Indication of Combination Therapy of Glufast and Insulin Sensitizer in Japan
February 24, 2009		KAPIDEX™ (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
February 20, 2009		Discontinuation of Development of TAK-242 for Severe Sepsis
February 14, 2009		ULORIC® (TMX-67, febuxostat) Receives FDA Approval for the Chronic Management of Hyperuricemia in Patients with Gout
February 12, 2009		Independent Data Monitoring Committee Recommends Resuming Enrollment of Non Squamous Nsclc Patients in the Motesanib MONET1 Trial
February 10, 2009		XOMA and Takeda Expand Collaboration
February 2, 2009		London Symphony Orchestra and Takeda celebrate 20 year partnership with launch of 8th Takeda Global Concert Series
February 2, 2009		Receipt of Takeda’s Attorney’s Fees in Takeda’s Patent case on ACTOS in the U.S.
January 31, 2009		FDA Approves KAPIDEX™ (dexlansoprazole) delayed release capsules for the Treatment of GERD
January 22, 2009		Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
January 21, 2009		New Drug Application Approval for ECARD® HD and ECARD LD in Japan
January 19, 2009		Review of Febuxostat New Drug Application to Continue after PDUFA Date
January 13, 2009		Appointment of New CEO of Takeda Pharmaceuticals Asia Private Limited